Clinical Study
Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
Table 2
Phenotype of harvest product.
| FG # | Total harvest ×109 | % viability | %CD3 harvest | %CD4 harvest | %CD8 harvest |
| 1 | 35 | 95 | 89 | 58 | 34 | 2 | 38 | 95 | 93 | 75 | 22 | 3 | 48.6 | 91 | 99 | 50 | 50 | 4 | 65.4 | 87 | 79 | 19 | 60 | 5 | 139 | 94 | 89 | 61 | 35 | 6 | 171 | 87 | 90 | 78 | 16 |
|
|